Activbiotics, Inc.

Centrexion Therapeutics Corporation

Activbiotics Pharma, LLC

Other

Arcion Therapeutics, Inc.

Arthur F Michaelis

William Bert Geiss

John Henry Van Duzer

Douglas Gregory Stafford

Xiang Y Yu

James N Campbell

Joseph Raker

James Michael Siedlecki

Yingfei Yang

Hawkins V Maulding

Chalom B Sayada

Bernard E Cabana

Gary Paul Magnant

Congxiang Zha

Barry Eisenstein

A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.

High concentration local anesthetic formulations

The invention features low-dosage rifalazil compositions which are useful for the treatment of bacterial infections.

Low dose rifalazil compositions

The invention features an ascending dose regimen for the administration of rifamycin-class antibiotics. The dosing regimen can be used to treat bacterial infections and diseases related to infection.

Regimen for the administration of rifamycin-class antibiotics

The present invention features rifamycin analogs and methods of using these compounds to treat a variety of microbial infections.

Rifamycin analogs and uses thereof

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3'-hydroxy analogs, and/or various fused ring systems with the benzene ring at the 4&#x2032;,5&#x2032; or 5&#x2032;,6&#x2032; positions.

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3'-hydroxy analogs, 4&#x2032;- and/or 6&#x2032; halo and/or alkoxy analogs, and various 5&#x2032; substituents that incorporate a cyclic amine moiety.

The invention features a method of delivering a drug to a diseased cell by linking the drug to a rifamycin derivative, compositions that include drug-rifamycin conjugates of the invention, and methods for treating disease using those compositions.

Targeted therapeutics and uses thereof

The invention features sulfhydryl rifamycin compositions, methods of making these compositions, and methods for treating disease using these compositions.

Sulfhydryl rifamycins and uses thereof

The invention features compounds that act as antimicrobial agents and/or antimicrobial enhancer agents, compositions that include the antimicrobial enhancer agents of the invention, and methods for treating microbial infections using those compositions.

Growing community of inventors

Devon, PA, United States of America

Arthur F Michaelis